Global TAVR Market to Hit $19.69 Billion by 2033, Driven by Aging Population and Minimally Invasive Innovations

Transcatheter Heart Valve Replacement Market Overview
The market for transcatheter heart valve replacement (THVR) is expanding significantly due to rising patient demand for minimally invasive treatments and advancements in technology. For patients with high surgical risk, transcatheter aortic valve replacement (TAVR) has emerged as the preferred option over open heart surgery. Globally, TAVR usage is growing, with North America and Europe leading the way in procedure numbers due to their sophisticated healthcare systems and favorable payment schemes. Rising healthcare awareness and improved medical facilities are driving the rapid growth of TAVR operations in Asia-Pacific nations, such as China and India. Market development, however, may be hindered by such problems as high procedural costs and limited reimbursement in certain areas. The THVR market is expected to continue expanding due to advancements in technology and increased patient access to cutting-edge cardiac treatments.

Type
• Transcatheter Aortic Valve Replacement
• Transcatheter Mitral Valve Replacement
• Transcatheter Pulmonary Valve Replacement

According to Renub Research, the Transcatheter Heart Valves Market is anticipated to grow at a compound annual growth rate (CAGR) of 12.00% from 2025 to 2033, from US$ 7.10 billion in 2024 to US$ 19.69 billion in 2033.
Transcatheter heart valve (THV) treatments are in high demand due to the increasing incidence of heart valve disorders, particularly among the elderly population. As conditions like mitral regurgitation and aortic stenosis become more prevalent, improved therapeutic options like THVs are required. According to September 2024 CDC research, 75% of American individuals know very little about heart valve disease. High-risk populations are also unaware of this, especially those 65 and older. In the United States, more than 5 million people are diagnosed with heart valve disease each year, and the ailment is responsible for over 25,000 deaths.

Material
• Mechanical valves
• Biological Valves

Key information covered in the report.
Base Year - 2024
Historical Period - 2021-2024
Market Forecast - 2025-2033
Market - US$ Billion

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=transcatheter-heart-valve-replacement-market-p.php

End-User
• Hospitals
• Ambulatory Surgical Centers
• Others

Growth Drivers of Transcatheter Heart Valve Replacement Market

• Rising Aging Population

One of the primary factors driving the expansion of the transcatheter heart valve replacement (THVR) market is the global aging population. The frequency of age-related cardiovascular diseases, especially aortic stenosis-a narrowing of the heart's aortic valve that obstructs blood flow-increases with life expectancy. People over 65 are more likely to have this ailment, and many of them are not good candidates for open heart surgery because of their fragility or other comorbidities. By providing a less intrusive option, transcatheter aortic valve replacement (TAVR) enables elderly patients to obtain life-saving care with a lower risk of surgery. The need for sophisticated, less invasive cardiac procedures, such as TAVR, is driven by the aging population, rising awareness of valve disorders, and early detection of these conditions.

• Preference for Procedures with Minimal Invasiveness

The growing preference for minimally invasive procedures among patients and doctors is a significant factor driving the demand for the THVR market. Large incisions, prolonged hospital stays, and protracted recovery times are all necessary for traditional open-heart surgery, which can be extremely risky, particularly for older or fragile patients. On the other hand, transcatheter heart valve replacement procedures, such as TAVR, require smaller incisions, typically through the femoral artery, resulting in shorter hospital stays, quicker recovery, and fewer complications. Many people choose this less intrusive method because it enhances patient comfort, safety, and results. More patients-even those with reduced surgical risk-are choosing transcatheter treatments as knowledge of these advantages increases and technology advances, which supports the market's ongoing growth and clinical uptake.

• Developments in Technology

The growth and development of the transcatheter heart valve replacement (THVR) market are significantly influenced by technological advancements. Advancements have greatly improved procedure accuracy, safety, and results in valve materials, design, and delivery methods. These days, imaging tools such as CT-guided navigation and 3D echocardiography enable more precise valve installation and patient evaluation. Furthermore, next-generation valves are designed to fit and last longer, which reduces the likelihood of issues such as leaks or device migration. Thanks to these advancements, a wider range of patients, including those with intermediate or even minimal surgical risk, can now benefit from transcatheter operations. By pushing the limits of minimally invasive heart valve treatment, ongoing research and development are increasing the effectiveness and accessibility of THVR.

To explore the full report, visit: https://www.renub.com/transcatheter-heart-valve-replacement-market-p.php

Countries
North America
• United States
• Canada
Europe
• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey
Asia Pacific
• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand
Latin America
• Brazil
• Mexico
• Argentina
Middle East & Africa
• Saudi Arabia
• UAE
• South Africa
Rest of the World

Long-Term Durability Concerns with TAVR about Open Heart Surgery

Present Knowledge about TAVR Durability

• Similar to surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR) has demonstrated encouraging mid-term durability, with studies showing low rates of structural valve degradation (SVD) and valve failure up to 5-6 years post-implantation.

• For instance, reintervention rates were less than 1% in both groups in the PARTNER and CoreValve trials, which showed comparable or even lower SVD rates with TAVR at 5 years when compared to SAVR.

• At 6 years, TAVR had a substantially lower rate of moderate to severe SVD (4.8%) than SAVR (24%), but rates of clinically meaningful valve failure were comparable, according to the NOTION study, which included low-risk patients over 70.

Concern Points and Unknowns
• Longer Limited Term Data Over 10 Years: There is a dearth of reliable data on valve durability after ten years, as the first TAVR valves were implanted in the early 2000s. It is unknown whether TAVR valves will remain as durable over extended periods as surgical bioprosthetic valves, which typically exhibit deterioration after 5-10 years.

• Valve Degeneration in Younger, Lower-Risk Patients: Durability issues become more significant when TAVR spreads into younger, lower-risk groups with longer life expectancies. In the long run, more definitive evidence is anticipated from ongoing studies such as PARTNER 3 and Evolut Low Risk.

• Leaflet thickening, calcification, or tearing are examples of structural valve deterioration (SVD), which results in valve malfunction. Although TAVR had low mid-term SVD rates, some early retrospective investigations indicated increased degeneration rates after 10 years; however, these findings were less definitive and had small sample sizes.

• In comparison to SAVR, TAVR is associated with a higher incidence of moderate or larger paravalvular leaks (PVLs), which may impact patient outcomes and long-term valve function. Modern gadgets, however, have lessened this risk.

• Pacemaker Implantation: Patients who undergo TAVR are more likely to require permanent pacemakers after the procedure, which may have an indirect impact on long-term outcomes.

Recent Developments

• Meril Life Sciences showcased its breakthroughs in valve replacement technology in November 2024 by introducing its Myval Octapro Transcatheter Heart Valve (THV) at significant cardiology conferences. The novel valve is designed to improve patient compatibility and procedure outcomes. Meril's commitment to improving treatment for structural heart disease is demonstrated by its continuous research and innovation.

• Abbott's experimental balloon-expandable transcatheter aortic valve implantation (TAVI) technology for patients with severe aortic stenosis was unveiled in November 2024. In addition to providing a less invasive treatment alternative for patients at high risk of open-heart surgery, this innovative device aims to enable AI-assisted treatments. The TAVI device, a contemporary alternative to traditional techniques, utilizes a balloon to inflate a replacement valve within the constricted aortic valve.

• For patients with symptomatic severe aortic stenosis, Medtronic announced in March 2024 that the FDA has authorized their Evolut FX+ transcatheter aortic valve replacement (TAVR) device. The diamond-shaped frame of this upgraded system provides improved coronary access while preserving the excellent valve performance for which the Evolut platform is renowned. Within two years, heart failure might result from severe aortic stenosis if treatment is not received.

Key Players Analysis
• Edwards Lifesciences
• Abbott Laboratories
• Medtronic Plc
• LIVANOVA PLC
• Boston Scientific Corporation
• Artivion, Inc.
• MicroPort Scientific Corporation
• Venus Medtech (Hangzhou) Inc.

New Publish Report
Animal Parasiticides Market: https://www.renub.com/animal-parasiticides-market-p.php
Bariatric Surgery Devices Market: https://www.renub.com/bariatric-surgery-devices-market-p.php
Europe Retinal Surgery Devices Market: https://www.renub.com/europe-retinal-surgery-devices-market-p.php

Contact US:
Company Name: Renub Research
Contact Person: Rajat Gupta
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: rajat@renub.com

About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

This release was published on openPR.